Ionis Pharmaceuticals (IONS) –
-
Form S-3ASR IONIS PHARMACEUTICALS
-
Form 4 IONIS PHARMACEUTICALS For: Nov 15 Filed by: KLEIN JOSEPH III
-
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
-
Form 144 IONIS PHARMACEUTICALS Filed by: KLEIN JOSEPH III
-
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
-
Ionis Pharmaceuticals (IONS) Present Positive Two-year Results from Phase 2 Study of donidalorsen
-
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
-
Ionis Pharmaceuticals (IONS) PT Raised to $45 at Morgan Stanley
-
Ionis Pharmaceuticals (IONS) PT Lowered to $85 at Wells Fargo
-
Ionis Pharmaceuticals (IONS) PT Raised to $48 at Morgan Stanley
-
Ionis to present at upcoming investor conferences
-
Ionis Pharmaceuticals (IONS) PT Raised to $28 at Goldman Sachs
-
Form 10-Q IONIS PHARMACEUTICALS For: Sep 30
-
Form 8-K IONIS PHARMACEUTICALS For: Nov 02
-
Ionis Pharmaceuticals (IONS) Reports In-Line Q3 EPS
-
Ionis reports third quarter 2023 financial results
-
Form 4 IONIS PHARMACEUTICALS For: Oct 01 Filed by: Baroldi Joseph
-
BofA Securities Upgrades Ionis Pharmaceuticals (IONS) to Neutral, 'Higher revenue potential'
-
Ionis to hold third quarter 2023 financial results webcast
-
Form 4 IONIS PHARMACEUTICALS For: Oct 16 Filed by: Swayze Eric
-
Form 4 IONIS PHARMACEUTICALS For: Oct 12 Filed by: Monia Brett P
-
Form 144 IONIS PHARMACEUTICALS Filed by: Monia Brett P
-
Form 144/A IONIS PHARMACEUTICALS Filed by: PARSHALL B LYNNE
-
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
-
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
-
Form 4 IONIS PHARMACEUTICALS For: Sep 28 Filed by: BENNETT C FRANK
-
Form 144 IONIS PHARMACEUTICALS Filed by: BENNETT C FRANK
-
Form 4 IONIS PHARMACEUTICALS For: Sep 26 Filed by: PARSHALL B LYNNE
-
Form 4 IONIS PHARMACEUTICALS For: Sep 26 Filed by: KLEIN JOSEPH III
-
Raymond James Starts Ionis Pharmaceuticals (IONS) at Strong Buy
-
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
-
Ionis Pharmaceuticals (IONS) PT Raised to $45 at Morgan Stanley
-
Form 8-K IONIS PHARMACEUTICALS For: Sep 27
-
Ionis Pharmaceuticals (IONS) enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
-
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
-
Form 144 IONIS PHARMACEUTICALS Filed by: PARSHALL B LYNNE
-
Form 144 IONIS PHARMACEUTICALS Filed by: KLEIN JOSEPH III
-
Form 8-K IONIS PHARMACEUTICALS For: Sep 26
-
Ionis Pharmaceuticals (IONS) Phase 3 study of olezarsen in people with familial chylomicronemia syndrome met its primary endpoint
-
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
-
Ionis to host investor and analyst day event
-
Form 4 IONIS PHARMACEUTICALS For: Aug 31 Filed by: BENNETT C FRANK
-
Form 4 IONIS PHARMACEUTICALS For: Aug 31 Filed by: Monia Brett P
-
Form 4 IONIS PHARMACEUTICALS For: Aug 31 Filed by: Geary Richard S
-
Ionis to present at upcoming investor conferences
-
Form 8-K IONIS PHARMACEUTICALS For: Aug 21
-
Form 8-K IONIS PHARMACEUTICALS For: Aug 21
-
Form 144/A IONIS PHARMACEUTICALS Filed by: Diaz Allene M.
-
Form S-8 IONIS PHARMACEUTICALS
-
Form 10-Q IONIS PHARMACEUTICALS For: Jun 30
Back to IONS Stock Lookup
